期刊文献+

芽胞杆菌来源沙奎那维的检测与分析

Formation and Determination of Saquinavir from Liquid Fermentation of Bacillus aryabhattai FJAT-14220
下载PDF
导出
摘要 对阿氏芽胞杆菌Bacillus aryabhattai FJAT-14220发酵液中沙奎那维成分进行分析与检测。采用高效液相四级杆飞行时间质谱(liquid chromatography-hybrid quadrupole time-of-flight mass spectrometry)分析阿氏芽胞杆菌FJAT-14220发酵液中胞外代谢物的成分。为获得代谢物的信息,首先采用MassHunter软件对原始数据进行分子特征提取,再通过Metlin数据库检索比对。在阿氏芽胞杆菌FJAT-14220发酵液中检测到883种代谢物,通过Metlin谱库搜索获得初步鉴定的有148种。其中,发现了具有生物活性的物质沙奎那维Saquinavir,其匹配得分达到93.08,占发酵液总代谢物相对含量的1.73%,保留时间为2.719 1 min,精确质量数为670.383 7。沙奎那维的发现为阿氏芽胞杆菌来源的多醚类抗生素的开发与利用提供理论依据。 Extracellular metabolites of Bacillus aryabhattai FJAT-14220 during fermentation were analyzed with liquid chromatography-hybrid quadrupole time-of-flight mass spectrometry. Saquinavir in the fermentation broth was targeted for the study. Molecular feature extraction and database retrieval were applied to access the information on the metabolites of B. aryabhattai. A total of 883 compounds were detected with 148 of them identified. The matching score of saquinavir was 93.08 with a relative concentration of 1.73%. Its retention time was 2. 7191 min; and, accurate mass, 670. 3837. The results could be the foundation for future development and utilization of saquinavir by B. aryabhattai fermentation.
出处 《福建农业学报》 CAS 北大核心 2016年第9期981-985,共5页 Fujian Journal of Agricultural Sciences
基金 公益性行业(农业)科研专项(201303094) 福建省农业科学院杰出青年人才基金项目(2014JQ-2) 福建省科技计划项目--省属公益类科研院所基本科研专项(2015R1018-11)
关键词 液相四级杆飞行时间质谱 阿氏芽胞杆菌 胞外代谢物 沙奎那维 liquid chromatography-hybrid quadrupole time-of-flight mass spectrometry Bacillus aryabhattai extracellular metabolites saquinavir
  • 相关文献

参考文献15

  • 1ANADOL E,KAISER R,VERHEYEN J,et al.Transmissionof human immunodeficiency virus I drug resistance-a casereport.What are the clinical implications? [J].EuropeanJournal of Medical Research.2010,15 (5):225-230.
  • 2PRIBIS J P,AL-ABED Y,YANG H,et al.The HIV proteaseinhibitor saquinavir inhibits HMGB1 driven inflammation bytargeting the interaction of cathepsin V with TLR4/MyD88[J].Molecular Medicine,2015,21:749-757.
  • 3BOFFITO M,JACKSON A,POZNIAK A,et al.Effect of amodified saquinavir/ritonavir dosing regimen with lower doselead-in phase on QTc interval,pharmacokinetics,antiviralactivity and safety in treatment-na ve HIV-1-infected patients[J].Drugs in R & D,2015,15 (1):141-153.
  • 4包雅琳.沙奎那韦的临床药理学和药物效应[J].国外医学(药学分册),1999,26(1):17-20. 被引量:4
  • 5余细勇.中草药与西药相互作用的机制探讨 [C]//第三届世界中西 医 结 合 大 会 论 文 集. 广 州:中 国 中 西 医 结 合 学 会,2007.
  • 6MARTIN R E,BUTTERWORTH A S,GARDINER D L,etal.Saquinavir inhibits the malaria parasite's chloroquineresistance transporter [J]. Antimicrobial Agents andChemotherapy,2012,56(5):2283-2289.
  • 7SHIVAGI S,CHATURVEDI P,BEGUM Z,et al.Janibacterhoylei sp.nov.,Bacillus isronensis sp.nov.and Bacillusaryabhattai sp. nov.,isolated from cryotubes used forcollecting air from the upper atmosphere[J].InternationalJouranal of Systematic and Evolutionary Microbiology,2009,59(12):2977-2986.
  • 8WEN J,REN C,HUANG N,et al.Draft genome of bagasse-degrading bacteria Bacillus aryabhattai GZ03from deep seawater [J].Marine Genomics,2015,19:13-14.
  • 9LEE S,KA J O,SONG H G.Growth promotion of Xanthiumitalicum by application of rhizobacterial isolates of Bacillusaryabhattai in microcosm soil [J].Journal of Microbiology,2012,50 (1):45-49.
  • 10SINGH Y,SRIVASTAV SK.Statistical and evolutionaryoptimization for enhanced production of an antileukemicenzyme, L-asparaginase,in a protease-deficient Bacillusaryabhattai ITBHU02isolated from the soil contaminated withhospital waste [J].Indian Journal of Experimental Biology,2013,51 (4):322-335.

二级参考文献38

  • 1卓锦明,徐兰,林永勉,江红,魏天恩,程振泰,郑卫.抗MRSA抗生素FW99501的分离纯化、结构鉴定和生物学活性[J].海峡药学,2006,18(2):153-156. 被引量:6
  • 2Kramer R A.HTLV-Ⅲ gag protein is processed in yeast cells by the virus pol-protease[J].Science,1986,231(4745):1580-1584.
  • 3Ghosh A K,Bilcer G,Schiltz G.Synthesis of FDA approved protease inhibitors[J].Synthesis,2001,15:2203-2229.
  • 4Richards A D,Roberts R,Dunn B M,et al.Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases[J].FEBS Lett,1989,247:113-117.
  • 5Kevin E B P,David J B,Peter H C,et al.Studies toward the large scale synthesis of the HIV proteinase inhibitor Ro 31-8959[J].J Org Chem,1994,59(13):3656-3664.
  • 6Gohring W,Gokhale S,Hilpert H,et al.Synthesis of the HIV-proteinase inhibitor saquinavir:a challenge for process research[J].Chimia,1996,50(11):532-537.
  • 7Gohring W.Process for the preparation of quinargine[P].US:5 914 404,1999-06-22.
  • 8Kottenhahn M,Drauz K,Hilpert H.Process for the production of a β-amino alcohol[P].US:5 994 555,1999-11-30.
  • 9Mohlin M H,Aesch P V.Process for producing amides using catalytic amounts of an N-hydroxy compound[P].US:5 536 816,1996-07-16.
  • 10Stephen W K,Vincent J K,Jay F D,et al.Viracept (nelfinavir mesylate,AG1343):a potent,orally bioavailable inhibitor[J].J Med Chem,1997,40(24):3979-3985.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部